Status:
COMPLETED
Bioequivalence Study Of Verapamil
Lead Sponsor:
Pfizer
Conditions:
Healthy Volunteers
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to demonstrate bioequivalence of single doses of two verapamil formulations
Eligibility Criteria
Inclusion
- Healthy male and/or female subjects
- Mass Index (BMI) of approximately 18 to 30 kg/m2
Exclusion
- Any condition possibly affecting drug absorption
- A positive urine drug screen
Key Trial Info
Start Date :
February 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2008
Estimated Enrollment :
79 Patients enrolled
Trial Details
Trial ID
NCT00668967
Start Date
February 1 2008
End Date
July 1 2008
Last Update
July 8 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
New Haven, Connecticut, United States, 06511